National Cancer Institute Grants $3M to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer

The National Institutes of Health’s National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate a Phase II clinical trial for the investigational drug, DDFPe, in the brain cancer, glioblastoma multiforme (GBM).


Link to press release...

Recent Posts

See All

Tucson, AZ, May 16th, 2022 - https://www.pr.com/press-release/861616 NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of prepara

Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases whe